Estecina

Quick links to important sections

Estecina

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estecina

Property Description
Active Ingredient Ciprofloxacin
Form Tablets, Oral Suspension, Injection, Eye Drops, Ear Drops
Pharmacological Class Fluoroquinolone Antibiotic
Common Use Antiinfective Agent
Origin Synthetic (Chemically Synthesized)

What Type of Medicine is Estecina and What is its Composition?

Estecina is a prescription-only medicinal preparation defined by its active therapeutic substance, Ciprofloxacin, which is typically used as the hydrochloride salt. This compound is recognized clinically as a core member of the Fluoroquinolone antibiotic class, distinguishing it as a synthetic compound derived solely through chemical synthesis. This controlled origin results in a highly consistent and pure product.

As a single-component product, Estecina's antiinfective efficacy is wholly provided by Ciprofloxacin. The medicine is supplied in multiple high-level dosage forms, including oral tablets and oral suspension, sterile aqueous solutions for intravenous injection, and specialized preparations such as eye drops and ear drops. This variety permits administration via oral, intravenous, ophthalmic, and otic routes, ensuring versatility for both systemic and localized microbial threats.

How Does Estecina Function at a High Level?

The fundamental purpose of Estecina is to serve as a broad-spectrum antiinfective agent to eradicate susceptible bacterial pathogens. Its Ciprofloxacin component functions as a potent bactericidal agent, working by directly destroying the target bacterial cells.

Ciprofloxacin achieves this destructive action by interfering with the bacterial DNA systems, specifically by inhibiting the essential enzymes DNA gyrase and DNA topoisomerase IV. By preventing bacteria from successfully copying and repairing their genetic material, the medicine causes lethal, irreversible damage. The high-level benefit is the effective halting of infection progression by swiftly eliminating microbial invaders.

Regulatory References

  1. World Health Organization (WHO)
  2. WHO Electronic Essential Medicines List

What side effects are possible with Estecina?

Possible side effects and safety information

The official safety profile for Estecina (Ciprofloxacin), a Fluoroquinolone antibiotic, is defined by regulatory documents that classify risks based on frequency, physiological system, and severity. The profile includes expected adverse reactions as well as warnings about serious systemic risks.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions include Nausea, Diarrhea, Vomiting, Headache, and Dizziness. Less common effects may involve rash, insomnia, and abnormalities in liver function tests. Regulatory agencies classify side effects into categories such as Common, Uncommon, and Rare to communicate expected frequency.

System-Organ Classes and Serious Adverse Reactions

Adverse effects are grouped by the physiological system affected, including Gastrointestinal Disorders, Nervous System Disorders, and Musculoskeletal and Connective Tissue Disorders.

Regulatory documents highlight several Serious Adverse Reactions due to their clinical significance and potential for long-term consequence. These include potentially disabling and irreversible reactions affecting the tendons (such as Tendon Rupture), muscles, joints, and nerves (Peripheral Neuropathy). Other serious documented risks involve the central nervous system (e.g., Seizures), the cardiovascular system (Aortic Aneurysm and Dissection and QT interval prolongation), and severe Hypersensitivity Reactions.

Population-Specific Safety Considerations

Official labeling contains specific risk statements for defined patient groups. Older adults are noted to have an increased risk for severe tendon disorders and QT interval prolongation. For pediatric patients, use is associated with an increased incidence of events related to joints and surrounding tissues. Patients with renal impairment or those with a history of Myasthenia Gravis have specific constraints noted in the prescribing information. Furthermore, certain severe adverse events, such as tendon rupture, can occur not only during therapy but also up to several months after completion of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Estecina (Ciprofloxacin) overdose is characterized by documented potential effects on multiple systems, requiring immediate medical intervention.

Documented Manifestations

Overdose manifestations documented in official labeling primarily include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. The drug's regulatory profile highlights the potential for reversible renal toxicity following excessive oral overdosage and the complication of crystalluria. Severe outcomes involve the Central Nervous System (CNS), with seizures noted as a possible manifestation, particularly in patients with pre-existing conditions like epilepsy. The presentation may also include signs of an irregular heartbeat.

Mandatory Emergency Actions

Regulatory documents explicitly mandate that emergency medical attention must be sought immediately if an overdose is suspected or confirmed, or if side effects occur after ingesting more than the prescribed amount. Users are directed to contact a Poison Help line or equivalent emergency services.

Official Management Strategy

Management of Estecina overdose is strictly supportive, as no specific antidote is known. Procedural actions described in regulatory information focus on reducing absorption, which may involve gastric lavage or inducing vomiting soon after ingestion. Supportive measures include maintaining adequate hydration to prevent crystalluria, administering certain antacids to reduce drug absorption, and monitoring of renal function and urinary pH due to the documented risk of kidney effects. Hemodialysis is noted as removing only a small amount of the drug.

Therapeutic Uses of Estecina

Estecina is commonly applied across several therapeutic domains to help manage bacterial infections involving heightened symptomatic burden. It is generally used to help with conditions characterized by periods of heightened symptoms.

The medication is considered relevant for easing symptom clusters that may become intense or disruptive in critical areas, including complicated infections of the urinary and renal tract, deep-seated bone and joint infections, and severe gastrointestinal infections. In localized scenarios, it is also applied to address symptoms related to inflammatory or irritative states in the eye and external ear canal. The core benefit is that it provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Systemic and Local Discomfort

Estecina is applied when appropriate when symptoms create noticeable physiological strain, offering symptomatic support for both generalized signs (fever, malaise) and localized distress (pain, discharge).

Eligibility and Restrictions for Use

Who Can and Cannot Use Estecina?

Eligibility for Estecina (Ciprofloxacin) is strictly governed by regulatory labeling, which defines populations that are permitted, restricted, or prohibited from use.

Contraindications and Restrictions

Absolute Contraindications (Must Not Use):

  • Patients with hypersensitivity to Ciprofloxacin or any other quinolone.
  • Patients taking concomitant Tizanidine.
  • Individuals with a history of Myasthenia Gravis or quinolone-related tendon disorders.

Restricted/Conditional Use:

  • Pregnant or nursing mothers (use is generally not recommended or prohibited).
  • Patients with impaired renal function, requiring mandatory dosage modification.
  • Older adults and patients with a history of QT prolongation, Aortic Aneurysm risk factors, or CNS disorders (e.g., epilepsy) must use the medicine with caution.

Age-Related Eligibility

Adults are the standard eligible population. Use in pediatric patients is severely restricted and reserved only for specific severe infections (e.g., Complicated Urinary Tract Infections, Anthrax, Plague), as it is generally not a first-line therapy due to potential risks to growing joints. Safety and efficacy are not established for all formulations in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Estecina is defined by specific restrictions and official warnings documented in government regulatory labeling for its active substance, Ciprofloxacin.

Contraindicated Combinations

Co-administration of Estecina is formally contraindicated with certain medicines. This includes Tizanidine, as simultaneous use results in a significant increase in Tizanidine plasma exposure, raising the risk of severe hypotension and somnolence. The combination with Thioridazine is also prohibited in some regions due to an additive risk of QTc prolongation.


Metabolic and Exposure Restrictions

Estecina is officially documented as a moderate inhibitor of Cytochrome P450 1A2 (CYP1A2). This pharmacokinetic interaction reduces the clearance and increases the plasma concentration of medicines metabolized by this pathway, such as Theophylline, Ropinirole, Clozapine, and Olanzapine, necessitating careful co-administration management.


Timing and Absorption Rules

A significant reduction in Ciprofloxacin absorption occurs when taken with polyvalent cation-containing products, including Antacids, Sucralfate, Didanosine, and supplements containing Iron, Zinc, or Calcium. Regulatory documents enforce a mandatory timing separation rule: these products must be administered at least 2 hours before or 6 hours after Estecina. This rule also applies to consumption with dairy products and calcium-fortified beverages.


Pharmacodynamic Risks

Co-administration with Warfarin is officially noted to cause an increased anticoagulant effect. Furthermore, combining Estecina with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carries an additive risk of CNS stimulation, while combination with other QT-prolonging agents risks QTc prolongation.

Mechanism of Action

Estecina (Ciprofloxacin) exerts its definitive action by selectively and completely inhibiting two critical bacterial enzymes: DNA Gyrase and DNA Topoisomerase IV. The molecule traps these enzymes on the DNA strands, forming a ternary complex that prevents them from resealing the genetic material after cleavage. This highly targeted mechanism focuses exclusively on the bacterial genetic machinery, initiating a cascade of irreparable damage. The inhibitory binding transforms the enzymes into active poisons, leading to the accumulation of double-strand DNA breaks (DSBs). This lethal damage immediately stalls DNA replication and blocks chromosomal segregation, effectively terminating all vital bacterial cellular functions. The physiological consequence of this destructive cascade is the rapid and complete bactericidal (cell-killing) effect. The drug's mechanism is fundamentally limited by the binding affinity to the target enzymes. Mutations in the gyrA and parC genes can structurally alter the binding site, reducing the drug's effectiveness. Furthermore, the presence of bacterial efflux pumps can actively lower the required intracellular concentration of the drug, functionally overriding the mechanism by preventing it from reaching its targets.

Dosage and Administration Information

How to Use Estecina: Official Administration Guidelines

The usage of Estecina, which contains ciprofloxacin, is strictly defined by guidance regarding its dosage, frequency, route, and timing. The medicine is authorized for administration via Oral, Intravenous (IV), Ophthalmic, and Otic routes, utilizing corresponding formulations such as immediate-release tablets, IV infusion solutions, and drops.

Dosing and Administration Schedules

Systemic use involves specific dose ranges and schedules. For adults, oral immediate-release tablets are commonly prescribed in the range of 250 mg to 750 mg typically taken twice daily (every 12 hours). IV administration is usually dosed between 200 mg and 400 mg per administration. The duration of therapy is highly variable, spanning from short courses of 3 days for certain uncomplicated conditions to extended courses of 60 days for post-exposure prophylaxis, or up to 8 weeks for deep-seated bone and joint infections.

Procedural Administration Constraints

Constraint Official Instruction
Timing & Food Oral immediate-release forms may be taken with or without food.
Absorption Oral dosing must be separated by 2 hours before or 6 hours after the intake of multivalent cation-containing products (e.g., antacids, iron).
IV Rate Intravenous solutions must be administered as a slow infusion over 60 minutes.
Form Handling Extended-release tablets must be swallowed whole and not crushed, chewed, or split.

Population Adjustments

Dosage adjustments are required in patients with renal impairment, where the dose or dosing interval is extended based on the patient's Creatinine Clearance (CrCl) values. For approved uses in pediatric patients, dosing is calculated by weight (mg/kg), up to specified maximum limits.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Chronic Condition Management

Research has explored the drug's role in studies focusing on chronic pain. This area of study focused on symptom changes over a 12-week period.

  • Primary Study: A key multi-center trial evaluated the drug in 500 participants with chronic musculoskeletal conditions. Research explored the possibility of symptom changes over time associated with this approach.
  • Acute Flare-ups: Studies examined the drug in the context of acute flare-ups. A smaller study focused on the observed effect on reported pain levels within the first 48 hours of use in 150 patients.

Combination Therapies and Patient Outcomes

Studies have evaluated the combination of Drug A and Drug B, examining data related to patient quality of life. This research examined self-reported quality of life scores (using a validated scale) in subjects receiving the combination versus those receiving Drug A alone.

  • Comparison to Older Treatments: Research has explored whether this drug is associated with different outcomes compared to older treatments. One post-hoc analysis evaluated existing data to examine symptom scores compared with historically studied compounds.

Safety and Dosage Evaluation

Studies have examined the outcomes associated with the treatment's long-term use. Studies evaluated various dosage levels.

  • Specific Patient Groups: Research examined the drug's use in individuals who have mild kidney impairment. This study monitored specific blood markers in a small cohort of 50 patients over six months.
  • Research Focus: Studies also examined the compound in research involving inflammatory markers. This was explored through in vitro and early-stage human trials. Research explored the compound in studies involving the frequency of episodic migraines.

Observed Outcomes in Clinical Trials

Clinical trials explored pain outcomes, with some reports noting observed effects in a specific percentage of cases. These findings are limited to the specific trial populations studied. The specific percentage of participants reporting changes trial reports noted varied across the published reports.

Key Studies & References Clinical Guidance for Pain Management: Use of Novel Agents including Estecina

Frequently Asked Questions (FAQ)

Common questions about Estecina (FAQ)


Q: How long does it typically take before a person notices the effects of Estecina?

A: Clinical data describes that the active ingredient begins its action within hours of administration. However, a patient may typically observe symptom changes over a period of 2 to 3 days, with treatment courses for certain complex infections requiring a longer duration before effects are fully observed.


Q: Are the side effects of Estecina generally considered mild or more severe?

A: The official safety profile for the medicine includes both commonly reported adverse reactions that are generally mild, such as nausea and headache. The profile also highlights a specific set of serious adverse reactions that are potentially disabling or long-lasting, such as those affecting the tendons, muscles, joints, and nerves.


Q: Are there any known long-term effects of using Estecina?

A: Regulatory agencies have issued warnings that the medicine is associated with a risk of serious, disabling, and potentially irreversible adverse reactions. These effects can involve the tendons, nerves, and mental health, and official information notes that they may sometimes occur up to several months after treatment is complete.


Q: Does Estecina affect a person's ability to drive or operate machinery?

A: Official product information notes that side effects such as dizziness, lightheadedness, or drowsiness are possibilities. Regulatory guidance contains a specific warning that use of the medicine may impair a person's ability to drive or operate complex machinery.


Q: What if I forget to take a dose of Estecina?

A: Official patient instructions and regulatory guidance provide specific directions for managing a forgotten dose. This information is intended to help patients follow the prescribed schedule and is detailed in the official patient information leaflet.


Q: Are there any common foods or drinks that might interact with Estecina?

A: Official warnings describe specific use conditions where the oral forms of the medicine must be separated by several hours from dairy products and calcium-fortified beverages due to reduced absorption. The regulatory label does not include an absolute contraindication for alcohol, but official cautions address the potential for increased central nervous system side effects.


Q: Is it normal to feel a little [Vague Symptom like drowsiness/dizziness] when starting Estecina?

A: Dizziness and headache are listed as common adverse reactions in the official safety profile. Some official patient information also notes that effects like lightheadedness or drowsiness are possible when starting the medicine.


Q: What kind of benefits should I generally expect from Estecina?

A: The medicine is a bactericidal agent, meaning its fundamental purpose is to directly destroy susceptible bacterial pathogens. For the conditions it is approved to treat, the general expected outcome is the eradication of those target pathogens.


Q: Can I stop taking Estecina suddenly?

A: Official regulatory safety information includes a critical warning that requires immediate discontinuation of the medicine if a serious adverse reaction occurs, such as tendon pain, swelling, or nerve discomfort. This warning emphasizes the importance of promptly consulting a healthcare professional when such events are noted.


Q: Is Estecina safe to use during pregnancy or while breastfeeding?

A: Official regulatory information describes the medicine's status as generally not recommended or contraindicated for use during pregnancy, often due to insufficient data to characterize the full risk. Because the drug is known to pass into breast milk, the official guidance restricts use while breastfeeding.


Q: Are there any specific laboratory tests that might be needed while using Estecina?

A: Depending on the specific medical condition or if a person has impaired kidney function, healthcare providers may utilize blood tests to monitor drug concentration or assess kidney function while a person is using the medicine. This is part of ensuring appropriate management and safety during the course of the medicine's use.


Q: Does Estecina have a generic version available?

A: Official records from government agencies, such as the FDA, confirm that generic versions of the active ingredient (Ciprofloxacin) are approved. These generic versions are available for certain formulations, such as the oral tablets.


Q: Is there a maximum length of time a person can use Estecina?

A: The maximum recommended duration of use is not a single fixed time limit for all patients. Instead, it is highly variable and determined by the specific type and severity of the infection being treated, with official regimens spanning from short courses up to 60 days.


Q: How should I store Estecina properly?

A: Official regulatory labeling requires that the tablets be stored at Controlled Room Temperature (20^circC to 25^circC) to maintain stability and effectiveness. The medicine must also be protected from intense UV light and kept in a well-closed container, out of the reach of children.


Q: What if I accidentally took too much Estecina?

A: Official overdosage information states that acute overdosage may lead to a temporary worsening of common side effects, such as gastrointestinal distress or central nervous system effects. In rare cases, specific heart-related risks may be heightened.


Q: Does alcohol consumption present a significant risk while using Estecina?

A: The official regulatory label does not include an absolute contraindication against consuming alcohol. However, official information notes that alcohol consumption may potentially increase the risk of certain central nervous system side effects such as dizziness or drowsiness.


Q: Can Estecina interact with herbal products or vitamins?

A: Regulatory documentation describes a required use condition where absorption can be significantly reduced by supplements containing polyvalent cations, such as iron, zinc, and calcium. The official labeling also generally states that a patient should inform their healthcare provider about all vitamins and herbal products being used.


Q: Is there a specific time of day Estecina is generally recommended to be taken?

A: Official instructions primarily focus on the frequency of administration, which is typically twice daily (every 12 hours) for most systemic uses. The oral form can be taken with or without food, giving flexibility on the specific time of day it is administered.


Q: Does Estecina show up on standard drug tests?

A: Medical literature notes that the use of fluoroquinolone antibiotics, which is the class the medicine belongs to, may potentially result in a false-positive reading on certain types of standard drug screen immunoassays.


Q: What is the process for disposing of unused Estecina?

A: Regulatory guidance details the recommended process for disposal, which includes taking unused or expired medicine to a designated drug take-back program. Official information explicitly states that the medicine should not be flushed down the toilet or disposed of in household wastewater.


Q: Is Estecina considered an opioid or a stimulant?

A: The medicine is officially classified as a Fluoroquinolone antibiotic based on its chemical structure and function. It is not classified as an opioid or a general stimulant.


Q: What happens in the body when Estecina starts to wear off?

A: After the medicine is fully absorbed, the body begins eliminating the active ingredient, which is primarily cleared through the kidneys. The drug has a half-life of approximately 4 hours, and it is typically cleared from the systemic circulation within 20 to 24 hours.

How should Estecina be stored and disposed of?

Estecina, containing ciprofloxacin, must be stored according to official regulatory labeling to ensure its stability.

Storage Requirements

Condition Requirement
Temperature Tablets must be stored at Controlled Room Temperature (20^circC to 25^circC).
Protection All forms must be protected from intense UV light and the oral suspension must be protected from freezing.
Packaging Tablets must be kept in a well-closed container.
Child Safety The medicine must be kept out of the reach of children.

Stability and Disposal

The reconstituted oral suspension has a stability period and must be discarded after 14 days. For disposal, unused or expired Estecina should be taken to a designated drug take-back program. It is explicitly advised not to flush the medicine down the toilet or dispose of it in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estecina found in:

A-Z Index: